FSGS (focal segmental glomerulosclerosis) is a rare kidney disease (RKD) with no specific FDA-approved therapy. Travere Therapeutics has one in its pipeline, though, and on June 10 launched an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback